Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer

The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for pemrolizumab in combination with axitinib for untreated patients with advanced or metastatic renal cell […]

read more

SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus combination was accepted following consideration […]

read more

SMC approves nivolumab plus ipilimumab combination for advanced RCC

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of nivolumab plus ipilimumab for intermediate-/poor-risk advanced renal cell carcinoma (RCC) by NHS Scotland. The nivolumab (Opdivo) plus ipilimumab (Yervoy) combination was accepted following consideration through the SMC’s Patient and […]

read more

First-line cabozantinib declined for a second time for use within NHS Scotland

Cabozantinib has been declined for a second time by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for people with untreated, intermediate-risk or poor-risk advanced renal cell carcinoma (RCC). KCSN are extremely disappointed with this decision, which was made despite new anecdotal evidence as to the effectiveness of the drug against advanced RCC submitted in response to […]

read more

Cabozantinib declined for use within NHS Scotland for first-line treatment of advanced kidney cancer

We are very disappointed by the Scottish Medicines Consortium’s (SMC) decision not to recommend cabozantinib (Cabometyx) for use within NHS Scotland as a first-line treatment option for people with intermediate-risk or poor-risk advanced renal cell carcinoma (RCC). This is despite cabozantinib’s proven effectiveness at significantly extending progression-free survival in these patients compared to first-line sunitinib, as shown in the […]

read more

First-line tivozanib approved for use in NHS Scotland

We are delighted that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS Scotland. Tivozanib, a tyrosine kinase inhibitor, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is […]

read more

Nivolumab and cabozantinib accepted for use within NHS Scotland for advanced kidney cancer

The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending two new kidney cancer medicines for routine use by NHS Scotland. Nivolumab (Opdivo), an immunotherapy for advanced kidney cancer, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is for medicines used at the end of life […]

read more

How Scotland plans to improve access to drugs for very rare diseases

The Scottish government has announced a set of measures aimed at giving it more flexibility in offering patient access to new expensive medicines for rare and end-of-life conditions.  Copyright 2016, Informa Business Intelligence, an Informa company. All rights reserved. The Scottish government has announced a set of measures aimed at giving it more flexibility in […]

read more

Nivolumab declined by Scottish Medicines Consortium for use within NHS Scotland

We are very disappointed (and confused!) by the Scottish Medicines Consortium’s (SMC) announcement yesterday that it will not be recommending nivolumab (Opdivo) for use within NHS Scotland as a treatment for advanced renal cell carcinoma after prior therapy in adults. This is despite nivolumab’s proven effectiveness at prolonging the life of kidney cancer patients compared […]

read more
Showing all 9 results
  TOP